Table 1.
Baseline characteristics of 109 patients with metastatic chromophobe RCC
| Entire cohort (N=109) | Sarcomatoid (N=29) | Non-sarcomatoid (N=80) | P-value (Fisher’s exact test) | |
|---|---|---|---|---|
| Age at diagnosis (years) – median (range) | 58 (40, 84) | 53 (40, 77) | 59 (40, 84) | 0.12 |
| Male gender | 60 (55%) | 17 (59%) | 43 (54%) | 0.65 |
| Diagnosed with de novo metastatic disease | 29 (27%) | 14 (48%) | 15 (19%) | 0.002 |
| IMDC risk | <0.001 | |||
| Favorable | 42 (42%) | 2 (7%) | 40 (56%) | |
| Intermediate | 42 (42%) | 18 (62%) | 24 (34%) | |
| Poor | 16 (16%) | 9 (31%) | 7 (10%) | |
| Nephrectomy | 0.002 | |||
| Yes | 103 (94%) | 28 (97%) | 75 (94%) | |
| No | 6 (6%) | 1 (3%) | 5 (6%) | |
| Primary tumor size cm-median(range) | 10.5(1.9-23) | 10.95(6.8-21) | 10.25(1.9-23) | |
| Symptoms | <0.001 | |||
| Asymptomatic | 40 (37%) | 4 (14%) | 36 (45%) | |
| Localized | 47 (43%) | 11 (38%) | 36 (45%) | |
| Systemic | 22 (20%) | 14 (48%) | 8 (10%) | |
| No. of metastatic sites | 0.13 | |||
| 1 | 61 (56%) | 12 (41%) | 49 (61%) | |
| 2 | 36 (33%) | 12 (41%) | 24 (30%) | |
| 3 | 10 (9%) | 5 (17%) | 5 (6%) | |
| Metastatic site | ||||
| Lymph nodes | 47 (43%) | 14 (48%) | 33(41%) | 0.5 |
| Lung | 37 (34%) | 18(62%) | 19(24%) | <0.001 |
| Bone | 34 (31%) | 5 (17%) | 29(36%) | 0.06 |
| Liver | 30(27%) | 6(21%) | 24(30%) | 0.40 |
| Peritoneal disease | 9(8%) | 1(3%) | 8(10%) | 0.40 |
| Adrenal | 4(4%) | 3(10%) | 1(1%) | 0.05 |
| Pancreas | 1(1%) | 1(3%) | 0(0%) | |